"Multifactorial risk factor approach is important for patients with T2DM", says Adie Viljoen. He presents a case of a patient with T2DM and multiple CV risk factors. Together with prof. Marx, he discusses the treatment plan for this patient.

Prof. Marx and Prof. Lehrke discuss a case of a 64-year old patient with T2DM and acute MI. What are the treatment options in this patient?

Tirzepatide has an agonistic effect not only on the GLP-1 receptor, but also on the glucose-dependent insulinotropic polypeptide (GIP) receptor. Whether this leads to substantial weight reduction in obese individuals without T2DM was investigated in the SURMOUNT-1 trial.

In this video, Prof. Tuttle discusses GLP-1RAs for CVD risk reduction and preservation of kidney function in CKD. Moreover, she talks about multidisciplinary team care for patients with T2DM and CKD.

GLP-1RAs may result in beneficial effects on renal outcomes, as shown by analyses of secondary endpoints in large trials. What are the potential mechanisms leading to CVD and CKD risk reduction?

EAS 2022 Prof. Laufs talks about the growing problem of obesity and treatment options for people with obesity, with a focus on GLP-1 receptor agonists.

Semaglutide reduces the risk of any first stroke in T2DM patients at high CVD risk, as revealed by an exploratory post-hoc analysis of the SUSTAIN 6 and PIONEER 6 trial . History of stroke had no influence on this effect.

Prof. Mann briefly discusses the KDIGO guidelines for treatment options in patients with T2DM and CKD. Furthermore, he provides an overview of kidney outcomes with GLP-1RAs in large trials.

Besides current recommendations of GLP-1RA therapy for patients with T2DM and comorbidities to reduce CV events, Frederik Persson discusses future possibilities for use of GLP-1RA. With question to test your knowledge.

There is a need for therapies for patients with low eGFR. Daniël van Raalte discusses whether GLP-1RA therapy can provide benefit for patients with T2DM and CKD. With question to test your knowledge.

Ofri Mosenzon discusses the importance of identification of CKD and how to prevent CKD progression in T2DM with older and newer therapeutic options. With question to test your knowledge.

Participants with obesity had, after 1 year, more effective body weight loss maintenance with a combination of liraglutide and exercise program compared to either single treatment alone.